The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Using machine learning to improve risk-stratification of AML: assessing age as a prognostic factor
Jan-Niklas Eckardt, MSc, MHBA, Technical University Dresden, Dresden, Germany, comments on the importance of considering age as a modulator of risk in acute myeloid leukemia (AML) patients, highlighting that conventional risk markers may not be universally applicable across different age groups. Dr Eckardt emphasizes that age-stratified game theory-informed machine learning of molecular alterations highlighted age as a significant factor; however, a more nuanced understanding of patient biology is needed to assess risk accurately. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
